Products and New Molecular Entities

Boehringer Ingelheim has brought a range of successful products from own drug discovery to market. A number of these drugs have either achieved blockbuster status with annual sales exceeding one billion US Dollar or have blockbuster potential. Continuously, our improvement initiatives have increased our research productivity and have resulted in a well-balanced pipeline showing a substantial number of new molecular entities and a high share of products in late phase development.

Successful Products from our own Research & Development

Product name
First launch
Active ingredient
Indication
Pradaxa®
2008

dabigatran

etexilate

Prevention of venous thromboembolic events (VTE) in adults

Spiriva®

Respimat Soft Mist™ Inhaler


Spiriva®

2007





2002



tiotropium



COPD

Micardis® 1998 telmisartan Essential hypertension

Sifrol® / Mirapex® /

Mirapexin®

2006



1997


pramipexole

Restless legs syndrome (RLS)



Parkinson's disease (PD)

Viramune® 1996 nevirapine HIV/AIDS

Promising Compounds in our Pipeline - Examples

Clinical phase
Compound*
Indication
Therapeutic principle
Mode of action
Phase III  

Dabigatran etexilate

(Pradaxa®)

 
Stroke Prevention in atrial fibrillation
Anticoagulation Oral direct inhibition of Thrombin

Acute venous thrombo-embolism (VTE)/

Secondary VTE

Phase III

Linagliptin

(Ondero®)

Diabetes mellitus
type II
DPP-IV antagonist
Dipeptidylpeptidase-IV inhibitor
Phase III
BI 10773 Diabetes mellitus type II  SGLT-2-antagonist  Inhibition of glucose transporter-2
Phase III
BIBF 1120 (Vargatef TM)
Primary indication:
Non-small cell
lung cancer (NSCLC)
Angiogenesis inhibition
Triple angiokinase inhibitor acting simultaneously on VEGFR, FGFR, PDGFR
Phase III
BIBW 2992 Primary indication:
Non-small cell
lung cancer (NSCLC)
Signal transduction inhibition
Dual irreversible EGFR/HER2 inhibitor
Phase III Flibanserin
(Girosa®)

Hypoactive
sexual desire
disorder (HSDD)
in pre-menopausal women


Serotonin receptor agonist and antagonist Neurotransmitter modulator
Phase II Dabigatran etexilate
(Pradaxa®)
Secondary prevention in acute coronary syndrome Anticoagulation Oral direct inhibition of Thrombin
Phase II
BI 6727
Variety of
cancer types
Cell-cycle kinase inhibition PLK-1 antagonist
Phase I
New compound
Variety of
cancer types

Cell-cycle kinase inhibition

Mitotic checkpoint inhibitor
Phase I  New compound Diabetes mellitus type II
11ß-HSD-1-antagonist

* These are investigational agents; their safety and efficacy have not yet been established.

Status: Aug. 2010